Northern Trust Corp Purchases New Position in MDxHealth SA (NASDAQ:MDXH)

Northern Trust Corp purchased a new stake in MDxHealth SA (NASDAQ:MDXH - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 436,062 shares of the company's stock, valued at approximately $1,033,000. Northern Trust Corp owned approximately 0.92% of MDxHealth at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Samjo Management LLC grew its stake in shares of MDxHealth by 130.9% during the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company's stock worth $4,324,000 after purchasing an additional 1,034,312 shares during the period. Perkins Capital Management Inc. boosted its holdings in MDxHealth by 31.6% during the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company's stock worth $2,331,000 after buying an additional 236,100 shares in the last quarter. Renaissance Technologies LLC grew its position in MDxHealth by 715.2% during the fourth quarter. Renaissance Technologies LLC now owns 123,100 shares of the company's stock worth $292,000 after buying an additional 108,000 shares during the period. Northern Right Capital Management L.P. acquired a new position in MDxHealth during the fourth quarter worth about $246,000. Finally, XTX Topco Ltd purchased a new position in MDxHealth in the fourth quarter valued at about $63,000.

MDxHealth Trading Down 1.4%

Shares of NASDAQ MDXH traded down $0.03 during midday trading on Friday, reaching $2.13. 45,968 shares of the stock were exchanged, compared to its average volume of 86,813. The stock has a 50 day moving average price of $1.72 and a 200-day moving average price of $1.86. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The company has a market capitalization of $100.72 million, a P/E ratio of -1.40 and a beta of 1.32. MDxHealth SA has a 52-week low of $1.35 and a 52-week high of $3.50.

MDxHealth (NASDAQ:MDXH - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The business had revenue of $24.29 million for the quarter, compared to analyst estimates of $22.62 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%. Equities research analysts expect that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of MDxHealth to a "hold" rating in a research report on Saturday, May 24th.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.